GlassScriptPhysician profile
Robert L Sweeten
NPI 1164509766
$3,991.42
in general payments reported to CMS, 2019-2025
36 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $209 · 2021: $485 · 2022: $599 · 2023: $815 · 2024: $993 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $617.11 | 2020-2025 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals LP | $587.23 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $517.38 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $287.16 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $281.72 | 2022-2023 | Ingrezza, Ongentys |
| Lilly USA, LLC | $263.28 | 2019-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $151.76 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $127.24 | 2019 | |
| Abbvie INC. | $120.09 | 2020-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.23 | 2025 | Caplyta |
| Amgen INC. | $80.89 | 2023 | Repatha, Otezla, Prolia |
| Abbott Laboratories | $80.01 | 2021-2025 | Freestyle Libre |
| Lundbeck LLC | $78.73 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.21 | 2023-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $59.58 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.92 | 2021 | |
| Aimmune Therapeutics, INC. | $55.31 | 2024 | |
| Pfizer INC. | $52.96 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.55 | 2024-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $47.24 | 2023 | |
| Allergan, INC. | $46.80 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.61 | 2022-2023 | |
| Amarin Pharma, INC. | $28.68 | 2019-2021 | |
| Biogen, INC. | $28.39 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $24.24 | 2025 | Spravato |
| Merck Sharp & Dohme LLC | $20.21 | 2023 | Gardasil 9, Vaxelis, Pneumovax 23 |
| Antares Pharma, INC. | $18.58 | 2024 | Xyosted |
| Apria Healthcare LLC | $17.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.67 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.33 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $14.42 | 2024 | |
| Mylan Specialty L.P. | $14.05 | 2023 | Yupelri |
| Dexcom, INC. | $13.71 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $13.16 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $12.49 | 2020 | |
| Corium, LLC | $9.98 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sweeten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.